Geneva Homologous Recombination Deficiency Test Is Predictive of Survival Benefit From Olaparib and Bevacizumab Maintenance in Ovarian Cancer
The Geneva HRD test predicts PFS and OS benefit from olaparib + bevacizumab. The potential detrimental effect of olaparib + bevacizumab on OS in the HRD-negative population is hypothesis-generating and needs to be confirmed prospectively.
Authors
- Jalid Sehouli (ORCID: https://orcid.org/0000-0002-5963-6623)
- Sana Intidhar Labidi‐Galy (ORCID: https://orcid.org/0000-0002-0824-3475)
- Antonio González-Martı́n (ORCID: https://orcid.org/0000-0001-8376-9576)
- Saverio Cinieri (ORCID: https://orcid.org/0000-0002-5555-0814)
- Sophie Clément (ORCID: https://orcid.org/0000-0003-1348-4887)
- Keiichi Fujiwara (ORCID: https://orcid.org/0000-0002-7388-0243)
- Liza Ho
- Germana Tognon (ORCID: https://orcid.org/0000-0003-3935-4992)
- Yann Christinat (ORCID: https://orcid.org/0000-0002-4977-1362)
- Viola A Heinzelmann-Schwarz (ORCID: https://orcid.org/0000-0002-5613-8629)
- Thomas McKee (ORCID: https://orcid.org/0000-0002-2147-3136)
- Catherine Genestie (ORCID: https://orcid.org/0000-0003-0927-1985)
- Éric Pujade-Lauraine (ORCID: https://orcid.org/0000-0002-0759-7263)
- Isabelle Laure Ray-Coquard (ORCID: https://orcid.org/0000-0003-2472-8306)
- Toon Van Gorp (ORCID: https://orcid.org/0000-0002-2564-721X)
- Sakari Hietanen (ORCID: https://orcid.org/0000-0003-4734-4743)
- V Kolovetsiou-Kreiner (ORCID: https://orcid.org/0000-0002-5561-5761)
Institutions
- Université Claude Bernard Lyon 1 (FR)
- University of Geneva (CH)
- Saab (Switzerland) (CH)
- Medical University of Graz (AT)
- Institut Gustave Roussy (FR)
- Turku University Hospital (FI)
- University Hospital of Basel (CH)
- Nordic Society of Gynecologic Oncology (DK)
- The European Academy of Gynaecological Surgery (BE)
- Hôpital Beau-Séjour (CH)
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT)
- Ospedale A. Perrino (IT)
- Centre Léon Bérard (FR)
- Saitama International Medical Center (JP)
- Arcagy Gineco (FR)
- Clinica Universidad de Navarra (ES)
- AGO Austria (AT)
- Spanish Ovarian Cancer Research Group (ES)
- Charité - Universitätsmedizin Berlin (DE)
- Saitama Medical University (JP)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2025-07-01
- DOI
- https://doi.org/10.1200/po-24-00825
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00